Compass Therapeutics, Inc. (CMPX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Core Insights - The company has seen a significant stock price increase of 290% year-to-date, outperforming the XBI index which is up 30% [1] - The company is focused on monoclonal antibody discovery and development in oncology, with three drugs currently in clinical trials [2] Clinical Programs Overview - The most advanced program is a DLL4 VEGF-A bispecific antibody named tovecimig, which is in a randomized trial for patients with advanced biliary tract cancer [3] - The company reported achieving the primary endpoint in a randomized trial, with the overall response rate more than tripling compared to the control arm [3]